answer text |
<p>On 11 November 2019, the National Institute for Health and Care Excellence (NICE)
published clinical guidelines on the prescribing of cannabis-based medicinal products
for people with intractable nausea and vomiting, chronic pain, spasticity and severe
treatment-resistant epilepsy. The guidelines recommend that cannabis-based medicinal
products are not offered to manage chronic pain in adults and that cannabidiol only
be offered as part of a clinical trial. NICE recognises the lack of evidence to support
the use of these medicines and recommends that further research is carried out on
the clinical and cost effectiveness as an add-on treatment for persistent treatment-resistant
neuropathic pain and chronic pain in adults, children and young people. Further information
and the clinical guidelines are available on the NICE website at the following link:</p><p><a
href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10124" target="_blank">https://www.nice.org.uk/guidance/indevelopment/gid-ng10124</a></p>
|
|